AstraZeneca's Recentin Plus FOLFOX4 to Earn 10 Percent Patient Share in the
Treatment of Colorectal Cancer by 2016
Physicians Indicate that Most Emerging Therapies Will Not Match the Current
Gold Standard, According to a New Report from Decision Resources
WALTHAM, Mass., April 2, 2008 /PRNewswire/ -- Decision Resources, one of
the world's leading research and advisory firms for pharmaceutical and
healthcare issues, forecasts that AstraZeneca's Recentin plus FOLFOX4 will
earn 10 percent patient share first-line stage IV colorectal cancer market in
the U.S. by 2016. Additionally, oncologists indicate that they would prescribe
this combination to 33 percent of their patients in the first-line setting for
stage IV colorectal cancer.
"Although oncologists interviewed are eager to prescribe Recentin plus
FOLFOX4, competition from the established Avastin will limit patient share,"
said Marcus Hoyle, analyst at Decision Resources. "According to oncologists
interviewed, physicians are gaining familiarity and comfort with prescribing
Avastin in the first-line setting, limiting the uptake of emerging agents."
According to the new report entitled Colorectal Cancer (Stage IV):
Therapies Must Increase Overall Survival over IFL plus Bevacizumab to Reach
Blockbuster Status, physicians indicate that the most promising emerging
therapies for the treatment of colorectal cancer will not match the current
gold standard, CAPOX plus bevacizumab. CAPOX plus bevacizumab consists of
Roche's Xeloda, Sanofi-Aventis's Eloxatin/Eloxatine, Yakult-Honsha's Elplat
plus Roche/Genentech/Chugai's Avastin. All three emerging therapies-
AstraZeneca's Recentin (plus FOLFOX4), Bristol-Myers Squibb/ImClone
Systems/Merck KGaA's Erbitux (plus FOLFIRI), and Pfizer's Sutent (plus
FOLFIRI)-consist of a targeted agent combined with an existing chemotherapy
regimen. Experts interviewed believe that all three emerging therapies will
demonstrate efficacy similar to that of currently available bevacizumab-
containing regimens. However, the safety and tolerability attributes of CAPOX
plus bevacizumab differentiate the regimen from all other current and emerging
therapies and ensure its gold-standard status through 2016.
About the Report
Colorectal Cancer (Stage IV): Therapies Must Increase Overall Survival
over IFL plus Bevacizumab to Reach Blockbuster Status is a DecisionBase 2008
report from Decision Resources. DecisionBase 2008 combines market forecasts
with clinical and commercial end points to assess market share projections in
35 indications. These outputs are driven by quantitative and qualitative
primary research. DecisionBase 2008 provides detailed market share, patient
share, and price-per-day projections for emerging drugs in development. The
market share projections are based on prescriber surveys that compare
physicians' expectations of a potential target product profile with an
emerging product profile of the leading drugs in development.
The report can be purchased by contacting Decision Resources. Members of
the media may request an interview with an analyst.
About Decision Resources
Decision Resources, Inc. (www.decisionresources.com) is a world leader in
market research publications, advisory services, and consulting designed to
help clients shape strategy, allocate resources, and master their chosen
markets. Decision Resources is a Decision Resources, Inc. company.
All company, brand, or product names contained in this document may be
trademarks or registered trademarks of their respective holders.
For more information, contact:
Elizabeth Marshall
Decision Resources, Inc.
781-296-2563
emarshall@dresources.com
SOURCE Decision Resources
Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com
